SCHEMBL25816449

SCHEMBL25816449

CC(C)(C)OC(=O)N1OC(O)C[C@H]1c1cncc(Br)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.37
UCHL1 P09936 1/20 0.37
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RORC P51449 3/20 0.33
ALDH1A1 P00352 2/20 0.33
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
DPP4 P27487 1/20 0.31
ELANE P08246 1/20 0.31
NR1H2 P55055 1/20 0.31
NR1H3 Q13133 1/20 0.31
HSD17B10 Q99714 1/20 0.31
KMT2A Q03164 1/20 0.31
GPR119 Q8TDV5 1/20 0.31
TAS1R3 Q7RTX0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30338629 1.00 USP30 (0.37) USP30UCHL1NPC1RAB9ASMN1; SMN2
SCHEMBL30339094 0.86 NTRK1 (0.39)
SCHEMBL25816482 0.86 NTRK1 (0.39)
SCHEMBL30339061 0.86 NTRK1 (0.39)
SCHEMBL25816476 0.86 NTRK1 (0.39)
SCHEMBL25816371 0.84 GPR119 (0.36) SMN1; SMN2ALDH1A1CHRM2CHRM1CHRM3
SCHEMBL25258471 0.84 ATM (0.39) USP30UCHL1NPC1RAB9ASMN1; SMN2
SCHEMBL30338645 0.84 GPR119 (0.42) ALDH1A1KMT2AGPR119
SCHEMBL30547529 0.84 ATM (0.39) USP30UCHL1NPC1RAB9ASMN1; SMN2
SCHEMBL25817689 0.84 GPR119 (0.42) ALDH1A1KMT2AGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116547281-A Isoxazolidines as RIPK1 inhibitors and uses thereof 赛诺菲 2023-08-04 CN disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 USP30 1354/4885UCHL1 1586/4885NPC1 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.